Product Profile Screening Activity Reports About
Log in/Sign up
Company search
Contact us
$5.75 million first close filed by IsoPlexis
XDATA - June 29th 2016
$5.75 million was raised by IsoPlexis according to information filed with the SEC. The company initiated a first close after selling 72% of its planned $8 million unregistered private offering. The non-brokered equity securities started to be sold to five investors almost two weeks ago. Based on the offering's structure, the company has until June 2017 to raise an extra $2.26 million. Two previous unregistered financing rounds raised an estimated $5.5 million.
IsoPlexis develops a single cell multiplexing immunoassay and software suite that provides in-depth biological characterization of important immune and cancer cell subsets. The company's tool enables discovery of novel biomarkers and accurate testing of molecules for clinical activity against these heterogeneous subsets. The tool is able to identify and characterize up to 45 secreted proteins on a single cell basis. Investors include Spring Mountain Capital and Yale Entrepreneurial Institute and Office of Cooperative Research.
Sean McKay (CEO) leads the Branford CT based company which was registered in 2014. IsoPlexis elected to keep its revenues undisclosed.
The board of directors includes Daniel Wagner, Gregory Ho, James Heath and Rong Fan.

The company has raised an estimated total of $11.25 million via private unregistered security offerings.
Offering recap
Status: First close
Company: IsoPlexis
Industry: Other Technology
Amount offered: $8 million
Amount placed: $5.75 million
SEC filing: Source
First sale: 06-17-2016
Data as of: 06-29-2016
Similar transactions 2015 Map: Biotech Category
2017-10-31 Cynvenio Biosystems unveils $3 million unregistered mezzanine placement
2017-10-30 PGDx files for first close after raising 59%
2017-10-16 Interpace Diagnostics Group closes $5 million warrant placement
2017-09-26 Bioarray Therapeutics reported the completion of a $5.22 million financing round
2017-09-21 $350,000 raised by CirculoGene Diagnostics as part of its mezzanine investment round
Largest Transactions by Amount Raised : Diagnostic Products
 Entity NameOffer Date $ SoughtDelta $ Sought$ RaisedSecurity OfferedIndustryFiling Type/
SEC Source
 Guardant Health2017-05-09320,419,351320,419,351320,419,351EquityBiotechnologyoriginal
 Adaptive Biotechnologies2015-05-05195,099,954195,099,954195,099,954EquityBiotechnologyoriginal
 True Health Group2017-01-26157,000,000157,000,000157,000,000EquityOther Health Careoriginal
 NantOmics2015-06-30150,000,000150,000,000150,000,000EquityBiotechnologyoriginal
 Adaptive Biotechnologies2014-04-04104,999,480104,999,480104,999,480EquityBiotechnologyoriginal
All dollar amounts are derived from filings lodged with the SEC by the company under current and previous names.
Blog Terms of Use Terms of Sale Privacy Policy
©2012-2016 XData/ Random Research, All Rights Reserved